Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) -positive breast cancers tend to be more aggressive and more likely to recur than HER2-negative breast cancers. However, novel anti-HER2 therapies have dramatically improved the prognosis of patients with HER2-positive breast cancer. CASE R...

Descripción completa

Detalles Bibliográficos
Autores principales: Takuwa, Haruko, Tsuji, Wakako, Yotsumoto, Fumiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198101/
https://www.ncbi.nlm.nih.gov/pubmed/30343261
http://dx.doi.org/10.1016/j.ijscr.2018.10.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198101/
https://www.ncbi.nlm.nih.gov/pubmed/30343261
http://dx.doi.org/10.1016/j.ijscr.2018.10.008

Ejemplares similares